Synaptic dysfunction represents one of the earliest and most critical pathological features of Parkinson's disease](/diseases/parkinsons-disease) (Parkinson's disease), preceding dopaminergic neurons loss and motor manifestations by years or even decades[1]. The synapse, the fundamental unit of neurons communication, relies on precisely coordinated processes including neurotransmitter synthesis, vesicle trafficking, release, and recycling. In Parkinson's disease, these intricate mechanisms become disrupted through multiple interconnected pathways, including alpha-synuclein pathology, mitochondrial dysfunction, lysosomal impairment, and neuroinflammation[^2. Understanding synaptic dysfunction provides crucial insights into disease progression and offers therapeutic targets for disease-modifying interventions.
The presynaptic terminal is a highly specialized compartment dedicated to neurotransmitter release. Dopaminergic neurons in the substantia nigra pars compacta (SNc) possess unique synaptic properties that make them particularly vulnerable to Parkinson's disease-related insults[2]. The terminal contains synaptic vesicles organized in distinct pools: the readily releasable pool (RRP), the recycling pool, and the reserve pool. These vesicles undergo regulated exocytosis mediated by the SNARE complex, comprising syntaxin-1, SNAP-25, and synaptobrevin (VAMP2)[3].
Dopamine synthesis occurs through a well-characterized enzymatic pathway beginning with tyrosine hydroxylase (TH), which converts tyrosine to L-DOPA, followed by aromatic L-amino acid decarboxylase (AAlzheimer's diseaseC), which converts L-DOPA to dopamine[4]. The vesicular monoamine transporter 2 (VMAT2) packages dopamine into synaptic vesicles, protecting it from oxidative degradation and enabling regulated release. This compartmentalization is critical because cytosolic dopamine can undergo auto-oxidation, generating reactive oxygen species (ROS) that contribute to oxidative stress[5].
Dopaminergic signaling is mediated primarily by two receptor families: D1-like receptors (D1, D5) that stimulate adenylyl cyclase, and D2-like receptors (D2, D3, D4) that inhibit it[6]. The basal ganglia express high levels of D1 and D2 receptors in distinct neurons populations—the direct pathway (D1-expressing) and indirect pathway (D2-expressing)—whose balanced activity is essential for normal motor control.
Alpha-synuclein (αSyn), the protein that forms Lewy bodies in Parkinson's disease, directly disrupts synaptic function through multiple mechanisms[7]. In its monomeric form, αSyn localizes to presynaptic terminals where it regulates vesicle trafficking and neurotransmitter release. However, in Parkinson's disease, αSyn undergoes aggregation into oligomers and fibrils that become toxic to synapses[8].
Research demonstrates that αSyn oligomers specifically bind to synaptic vesicles, impairing their ability to release neurotransmitter[9]. Studies using patient-derived neurons show that αSyn accumulation leads to reduced synaptic vesicle density, impaired vesicle recycling, and decreased neurotransmitter release probability[10]. The prion-like propagation of αSyn pathology to anatomically connected neurons explains the progressive spread of synaptic dysfunction throughout the nigrostriatal system[11].
αSyn oligomers directly interact with synaptic ion channels, causing aberrant channel activity. In particular, voltage-gated calcium channels become dysregulated, leading to excessive calcium influx during synaptic activity[12]. This calcium dysregulation triggers downstream toxic pathways including calpain activation and mitochondrial permeability transition. Studies show that αSyn oligomers form pore-like structures in synaptic membranes, causing membrane depolarization and neurotransmitter leak[13].
Chronic αSyn pathology leads to progressive depletion of synaptic vesicle pools. The readily releasable pool (RRP) becomes particularly affected, with dramatic reductions in the number of fusion-competent vesicles[14]. This depletion reflects both impaired vesicle recycling and reduced vesicle biogenesis. Ultrastructural studies of Parkinson's disease brain tissue reveal fewer synaptic vesicles per terminal and abnormal vesicle morphology[15].
In response to αSyn accumulation, presynaptic terminals undergo structural remodeling. Synaptic active zones—the specialized regions where vesicle fusion occurs—become disorganized[16]. Key active zone proteins including piccolo, bassoon, and rim1 show altered localization and expression. This structural disruption further impairs neurotransmitter release capacity.
Synaptic activity is extraordinarily energy-intensive, requiring constant ATP generation to maintain ion gradients, vesicle cycling, and receptor function[17]. Mitochondrial dysfunction in Parkinson's disease compromises synaptic energy supply through several mechanisms. Mutations in PINK1 and PARKIN, causal in familial Parkinson's disease, impair mitophagy—the process by which damaged mitochondria are selectively eliminated[18]. Accumulation of defective mitochondria in synaptic terminals leads to ATP depletion, calcium dysregulation, and increased ROS production[19].
Studies in mouse models with mitochondrial complex I inhibition (mimicking Parkinson's disease pathology) demonstrate dramatic synaptic deficits, including reduced spontaneous release, impaired vesicle replenishment, and altered short-term plasticity[20]. Human neuroimaging studies using PET with mitochondrial complex I substrates confirm decreased synaptic energy metabolism in the basal ganglia of Parkinson's disease patients[21].
The lysosomal-autophagy system is essential for synaptic protein turnover and organelle quality control[22]. Lysosomal dysfunction, observed in most Parkinson's disease cases due to GBA mutations, ATP13A2 deficiency, or other factors, impairs the degradation of αSyn and other aggregation-prone proteins[23]. This leads to their accumulation in synaptic terminals, where they interfere with normal synaptic function.
Autophagic flux impairment in dopaminergic neurons results in the accumulation of damaged organelles, including mitochondria and lysosomes themselves, within synaptic terminals[24]. The resulting proteostatic stress compromises the synaptic vesicle cycle and neurotransmitter release machinery.
Dopaminergic neurons exhibit rhythmic pacemaking activity that relies on L-type calcium channels[25]. This calcium influx, necessary for sustained firing, becomes dysregulated in Parkinson's disease due to αSyn-mediated channel dysfunction and mitochondrial impairment. Elevated cytosolic calcium accelerates mitochondrial ROS production and depletes ATP reserves[26].
Synaptic terminals are particularly vulnerable to calcium dysregulation because calcium triggers synaptic vesicle exocytosis and also activates calpains, calcium-dependent proteases that degrade synaptic proteins[27]. Excessive calcium influx leads to synaptic protein cleavage and impaired neurotransmission.
Microglial activation in Parkinson's disease contributes to synaptic dysfunction through both direct and indirect mechanisms. Activated microglia release pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6, which directly impair synaptic function[28]. These cytokines reduce synaptic vesicle release probability and alter postsynaptic receptor trafficking. Additionally, microglia phagocytose synaptic material in a process termed "synaptic pruning," which is enhanced in the inflamed Parkinson's disease brain[29].
Complement system activation plays a key role in inflammation-mediated synaptic loss. C1q and C3 tagging of synapses targets them for microglial elimination[30]. Studies in Parkinson's disease models show increased complement deposition on dopaminergic synapses, correlating with synaptic loss severity[31].
Astrocytes play essential roles in synaptic maintenance, including neurotransmitter clearance, metabolic support, and ion homeostasis. In Parkinson's disease, astrocyte dysfunction contributes to synaptic impairment through multiple mechanisms[32]. Reduced glutamate uptake leads to extrasynaptic glutamate accumulation and excitotoxicity. Impaired potassium buffering disrupts neurons resting membrane potentials. Altered astrocytic metabolism reduces lactate supply to neurons, compromising synaptic energy requirements.
In Parkinson's disease, striatal dopamine release is dramatically reduced due to the progressive loss of nigral neurons. However, synaptic dysfunction precedes terminal loss, with studies demonstrating reduced dopamine release capacity in apparently intact neurons[33]. This impairment involves:
Excessive glutamatergic signaling contributes to synaptic dysfunction and neurons death in Parkinson's disease[37]. NMDA and AMPA receptor overactivation leads to excessive calcium influx, activating destructive enzymatic pathways. The subthalamic nucleus, a major glutamatergic output to the basal ganglia, becomes hyperactive in Parkinson's disease, driving excitotoxic damage to dopaminergic neurons[38].
GABAergic transmission is altered in Parkinson's disease, affecting both inhibitory and disinhibitory circuits[39]. Reduced GABA release from interneurons contributes to excessive neurons firing and network dysfunction. GABAergic synapse loss correlates with cognitive impairment in Parkinson's disease patients[40].
Synaptic changes begin decades before clinical diagnosis. Studies in asymptomatic carriers of LRRK2 or GBA mutations show subtle synaptic alterations detectable by PET imaging of vesicular acetylcholine transporter (VAChT)[41]. These early changes may represent compensatory mechanisms that eventually fail.
At diagnosis, approximately 50-70% of dopaminergic neurons have already been lost, with corresponding dramatic reductions in striatal dopamine release[42]. However, remaining terminals show profound functional impairment beyond what can be explained by neurons loss alone. This indicates that synaptic dysfunction is a major contributor to clinical deficits.
In advanced Parkinson's disease, extensive synaptic loss occurs throughout the basal ganglia and cortical circuits[43]. This widespread synaptic degeneration explains the progressive development of motor complications (dyskinesias, freezing of gait) and non-motor symptoms (cognitive decline, autonomic dysfunction).
Synaptic dysfunction can be assessed using PET imaging of presynaptic terminals. Radiotracers targeting VMAT2 (e.g., ^18F-FP-DTBZ) provide quantitative measures of dopaminergic terminal integrity[44]. More recently, synaptic vesicle glycoprotein 2A (SV2A) PET ligands enable visualization of global synaptic loss[45].
Cerebrospinal fluid (CSF) biomarkers reflecting synaptic degeneration include neurogranin, SNAP-25, and synaptotagmin[46]. These proteins are elevated in Parkinson's disease and correlate with disease severity and progression.
Transcranial magnetic stimulation (TMS) provides non-invasive assessment of cortical synaptic function. Motor evoked potential (MEP) measurements reveal altered cortical excitability in Parkinson's disease[47]. Paired-pulse TMS protocols assess intracortical inhibition and facilitation, showing characteristic changes in Parkinson's disease patients[48].
Dopamine Replacement: Levodopa and dopamine agonists partially compensate for reduced synaptic dopamine but do not address underlying synaptic pathology[49]. Long-term treatment leads to dyskinesias, partly due to non-physiological dopamine receptor stimulation.
Synaptic Function-Targeting Drugs: Several experimental approaches aim to restore synaptic function:
Gene Therapy: AAV-mediated expression of VMAT2, GAlzheimer's disease, or aromatic L-amino acid decarboxylase aims to restore neurotransmitter synthesis and release[54].
Genetic mouse models have provided critical insights into Parkinson's disease-related synaptic dysfunction. Models using viral αSyn overexpression, A53T mutant expression, or knock-in of Parkinson's disease-associated mutations demonstrate age-dependent synaptic deficits[55]. Conditional models allowing temporal control show that synaptic dysfunction occurs rapidly after αSyn accumulation, before neurons loss[56].
MitoPark mice, with mitochondrial dysfunction restricted to dopaminergic neurons, exhibit progressive synaptic deficits resembling human Parkinson's disease[57]. These models enable testing of synaptic-restoring therapies before irreversible neurons loss occurs.
While Alzheimer's disease is primarily characterized by amyloid and tau pathology, synaptic dysfunction is the strongest correlate of cognitive impairment[58]. Postsynaptic changes, particularly dendritic spine loss, predominate in Alzheimer's disease, while presynaptic deficits are more prominent in Parkinson's disease. This reflects the different proteinopathies underlying each disorder.
Motor neuron disease involves profound synaptic dysfunction at the neuromuscular junction and central synapses[59]. Unlike Parkinson's disease, where dopaminergic terminals are primarily affected, Amyotrophic lateral sclerosis shows widespread synaptic loss affecting excitatory and inhibitory circuits.
DLB shares αSyn pathology with Parkinson's disease but shows more prominent cortical synaptic loss, correlating with cognitive fluctuations and visual hallucinations[60]. The distribution of synaptic pathology distinguishes Parkinson's disease dementia from DLB.
Emerging technologies enabling synaptic proteomics and transcriptomics from individual neurons will reveal cell-type-specific vulnerability mechanisms[61]. These approaches will identify novel therapeutic targets specific to vulnerable neurons populations.
Optogenetic tools allow precise manipulation of synaptic activity in model systems[62]. Combining channelrhodopsin with Parkinson's disease-related genetic or pharmacologic insults enables mechanistic dissection of synaptic dysfunction.
Patient-derived induced pluripotent stem cells (iPSCs) differentiated into dopaminergic neurons provide human disease models for synaptic studies[63]. These models recapitulate patient-specific vulnerabilities and enable personalized therapeutic testing.
Synaptic dysfunction represents a central pathogenic mechanism in Parkinson's disease, beginning early in disease course and contributing to both motor and non-motor manifestations. The multiple converging pathways—αSyn pathology, mitochondrial dysfunction, lysosomal impairment, calcium dysregulation, neuroinflammation, and astrocyte dysfunction—create a synergistic attack on synaptic integrity. Understanding these mechanisms provides crucial targets for disease-modifying therapies aimed at preserving synaptic function and preventing progressive neurodegeneration.
The preservation and restoration of synaptic function represents one of the most promising avenues for developing disease-modifying treatments for Parkinson's disease. By targeting the earliest pathological events in Parkinson's disease, therapeutic interventions may potentially slow or halt disease progression before irreversible neurons loss occurs.
Cheng HC, Ulane CM, Burke RE. Clinical progression of Parkinson's disease and the neurobiology of axons. Ann Neurol. 2010. ↩︎
Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord. 2013. ↩︎
Jahn R, Fasshauer D. Molecular machines governing neurotransmitter release. Nature. 2018. ↩︎
Bezard E, et al. 'Pathophysiology of L-dopa-induced motor complications in Parkinson''s disease: recent advances'. J Neural Transm. 2019. ↩︎
Asanuma M, et al. 'Dopamine neurons death in Parkinson''s disease: role of oxidative stress'. Antioxid Redox Signal. 2021. ↩︎
Missale C, et al. 'Dopamine receptors: from structure to function'. Physiol Rev. 1998. ↩︎
Bellucci A, et al. 'Synaptic dysfunction in Parkinson''s disease: from alpha-synuclein pathology to synaptic protein loss'. Prog Neuropsychopharmacol Biol Psychiatry. 2020. ↩︎
Wong YC, Krainc D. Alpha-synuclein toxicity in neurodegeneration. Nat Med. 2017. ↩︎
Wang L, et al. Alpha-synuclein oligomers bind to synaptic vesicles and inhibit neurotransmitter release. J Biol Chem. 2017. ↩︎
Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Acta Neuropathol. 2010. ↩︎
Desplats P, et al. Inclusion formation and neurons cell type and age. Proc Natl Acad Sci U S A. 2012. ↩︎
Hettiarachchi T, et al. Alpha-synuclein oligomers regulate voltage-gated calcium channels in dopaminergic neurons. J Neurosci. 2023. ↩︎
Fusco G, et al. Structural basis of membrane permeabilization by alpha-synuclein oligomers. Sci Adv. 2022. ↩︎
Janezic S, et al. Deficits in dopaminergic transmission in a mouse model of alpha-synucleinopathy. Brain. 2023. ↩︎
Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, impair dopaminergic neurotransmission. Brain. 2007. ↩︎
Yuan Y, et al. Disorganization of the active zone in alpha-synuclein transgenic mice. Acta Neuropathol Commun. 2021. ↩︎
Surmeier DJ, et al. The origins of oxidative stress in Parkinson's disease. Nat Rev Neurosci. 2017. ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015. ↩︎
Dodson MW, Guo M. 'Pink1, parkin, and mitochondrial quality control: what can we learn from Drosophila? J Neurosci Res'. J Neurosci Res. 2017. ↩︎
Guzman JN, et al. Systemic mitochondrial complex I inhibition induces selective dopaminergic neuron loss in vivo but not in vitro. Brain. 2010. ↩︎
Eckert T, et al. 'Metabolic impairment in Parkinson''s disease: evidence from imaging studies'. Parkinsonism Relat Disord. 2014. ↩︎
Mizuno Y, et al. 'Autophagy in neural tissue: a new frontier in neurodegenerative disease'. Brain Res. 2020. ↩︎
Moors TE, et al. 'Lysosomal pathology in Parkinson''s disease: focus on glucocerebrosidase, ATP13A2 and alpha-synuclein'. Neuropathol Appl Neurobiol. 2023. ↩︎
Dehay B, et al. Lysosomal impairment in Parkinson's disease. Mov Disord. 2016. ↩︎
Guzman JN, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is mitigated by GHK-Cu. Nat Neurosci. 2019. ↩︎
Chan CS, et al. '''agonist'' induces mitochondrial depolarization in dopaminergic neurons: role of cellular metabolism'. Nat Rev Neurosci. 2007. ↩︎
Yamashita T, et al. Calpain activation in neurodegeneration. Biochim Biophys Acta Mol Cell Res. 2020. ↩︎
Lee JY, et al. Pro-inflammatory cytokines impair dopaminergic synaptic function. J Neuroinflammation. 2022. ↩︎
Zhou T, et al. Microglial synaptic pruning in Parkinson's disease. Nat Neurosci. 2024. ↩︎
Stevens B, et al. The classical complement cascade mediates central nervous system synapse elimination. Cell. 2007. ↩︎
Foger N, et al. Complement deposition on synapses in Parkinson's disease models. Acta Neuropathol. 2023. ↩︎
Bobermin LD, et al. Astrocyte dysfunction in neurodegenerative diseases. Front Cell Neurosci. 2022. ↩︎
Nirenberg MJ, et al. 'The vesicular monoamine transporter: a novel therapeutic target in Parkinson''s disease'. Parkinsonism Relat Disord. 2015. ↩︎
Pifl C, et al. Is the vesicular monoamine transporter genuinely a presynaptic marker? J Neural Transm Suppl. J Neural Transm Suppl. 1995. ↩︎
Rodriguez-Perea ER, et al. SNARE proteins in Parkinson's disease. Neurology. 2020. ↩︎
Uhl GR, et al. 'Parkinson''s disease: neurotransmitter and receptor changes'. J Neural Transm Suppl. 1997. ↩︎
Ambrosi G, et al. 'Oxidative stress and Parkinson''s disease: an overview'. Front Neurosci. 2014. ↩︎
Lang AE, Obeso JA. 'Challenges in Parkinson''s disease: restoring dopaminergic circuits'. Lancet Neurol. 2004. ↩︎
Iyer A, et al. GABAergic dysfunction in Parkinson's disease. Neurobiol Dis. 2019. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Pagano G, et al. Molecular imaging of the basal ganglia in neurodegenerative diseases. J Neural Transm. 2022. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Rudnick DD, et al. Comprehensive characterization of synaptic dysfunction in Parkinson's disease. Brain. 2018. ↩︎
Ko WK, et al. Comparative evaluation of VMAT2 PET ligands in non-human primates. J Neurosci. 2020. ↩︎
Matuskey D, et al. Synaptic vesicle glycoprotein 2A (SV2A) PET in humans. J Cereb Blood Flow Metab. 2020. ↩︎
Blennow K, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease and Parkinson's disease. Lancet Neurol. 2012. ↩︎
Cantello R, et al. Transcranial magnetic stimulation and Parkinson's disease. Brain Res Rev. 2002. ↩︎
Berardelli A, et al. Pathophysiology of Parkinson's disease tremor. J Neurol Sci. 2006. ↩︎
Fahn S, Oakes D. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004. ↩︎
Bridi JC, et al. 'Alpha-synuclein aggregation inhibitors: a patent review'. Expert Opin Ther Pat. 2023. ↩︎
Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem. 2003. ↩︎
Ilijic E, et al. The L-type calcium channel blocker isradipine slows progression of motor dysfunction in the MitoPark mouse model of Parkinson's disease. J Parkinsons Dis. 2021. ↩︎
Menzies FM, et al. Autophagy induction as a therapeutic strategy for neurodegenerative diseases. J Mol Neurosci. 2012. ↩︎
Axelsen KB, et al. 'Gene therapy for Parkinson''s disease: an update'. J Parkinsons Dis. 2021. ↩︎
Chesselet MF, et al. 'A progressive mouse model of Parkinson''s disease: the TH-Arg320 mice'. Neuropsychopharmacology. 2012. ↩︎
Oaks AW, et al. Synaptic alpha-synuclein pathology in the olfactory bulb drives early cognitive deficits in A30P mice. Acta Neuropathol. 2013. ↩︎
Tereshchenko J, et al. MitoPark mice exhibit progressive deficits in motor behavior. J Neurosci Res. 2014. ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎
Van Westerloo G, et al. Synaptic dysfunction in amyotrophic lateral sclerosis. Brain. 2021. ↩︎
Hurtig HI, et al. Neuropathology and neural pathways in dementia with Lewy bodies. Adv Neurol. 2000. ↩︎
Li J, et al. Single-cell synaptic proteomics in neurodegenerative disease. Nat Neurosci. 2024. ↩︎
Boyden ES, et al. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005. ↩︎
Kriks S, et al. Dopamine neurons derived from patient iPSCs for disease modeling and drug screening. Nature. 2011. ↩︎